期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 17, 期 10, 页码 1462-1470出版社
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2011.03610.x
关键词
Immunology; vaccine; visceral leishmaniasis
资金
- Medical Research Council [G1000230, G0400786] Funding Source: researchfish
- MRC [G1000230, G0400786] Funding Source: UKRI
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据